V0162 a new long-acting bronchodilator for treatment of chronic obstructive lung diseases: preclinical and clinical results

Table 4 V0162 pharmacokinetic parameters for different dose cohorts in healthy volunteers and in COPD patients

V0162 dose	t_max (h)	C_max (pg/mL)		AUC_0-t (h.pg/mL)		t_1/2 (h)
Healthy volunteers	Median	Mean	SD	Mean	SD	Mean	SD
10 μg	nc	nc	nc	nc	nc	nc	nc
50 μg	0.08	40	14	555	790	26	13
100 μg	0.08	108	41	1872	1981	19	0.69
200 μg	0.08	149	33	4578	2633	28	11
400 μg	0.08	431	268	6529	3774	23	8.08
800 μg	0.08	1030	311	17670	13735	19	4.88
1200 μg	0.08	2180	2030	17646	12297	20	11
1600 μg	0.08	2270	618	32692	13447	36	15
2000 μg	0.08	2970	1800	41192	37151	19	3.55
2400 μg	0.10	2840	1040	26820	16211	17	3.40
100 μg + charcoal	0.08	98	65	560	250	21	3.99
200 μg + charcoal	0.08	81	28.8	1483	411	32	13
400 μg + charcoal	0.08	359	216	3541	1871	27	8.32
2400 μg + ipratropium/fenoterol	0.11	2600	824	31200	9941	19	4.17
COPD patients
1600 μg	0.08	1040	577	13872.8	6461	nc	nc

nc not calculated (more than 50 % of plasma values were below the lower limit of quantification (5.00 pg/mL)

ISSN: 1465-993X